Compare YORW & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | YORW | TECX |
|---|---|---|
| Founded | 1816 | 2019 |
| Country | United States | United States |
| Employees | 104 | 60 |
| Industry | Water Supply | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.4M | 554.1M |
| IPO Year | 1994 | N/A |
| Metric | YORW | TECX |
|---|---|---|
| Price | $29.53 | $29.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $34.00 | ★ $75.20 |
| AVG Volume (30 Days) | 163.9K | ★ 179.4K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $77,488,000.00 | N/A |
| Revenue This Year | $11.78 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | $88.39 | ★ N/A |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $28.26 | $14.39 |
| 52 Week High | $34.30 | $35.99 |
| Indicator | YORW | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 50.54 |
| Support Level | $28.26 | $27.74 |
| Resistance Level | $32.13 | $31.88 |
| Average True Range (ATR) | 0.61 | 1.77 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 57.03 | 62.04 |
The York Water Co is the investor-owned water utility in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. The company also owns and operates three wastewater collection systems and twelve wastewater collection and treatment systems. The company operates within its franchised water and wastewater territory, which covers portions of municipalities within four counties in south-central Pennsylvania. It provides services to diversified, manufacturing such items as fixtures and furniture, electrical machinery, food products, paper, ordnance units, textile products, air conditioning systems, laundry detergent, barbells, and motorcycles.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.